PapersPMID:19593179
A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder.
- findings
- 4
- compound
- 1
- endpoints
- 4
- no difference found
- 3
- Study, every finding
- RCT · 8 weeks
- Dose studied, every finding
- 220 mg capsules, 1 daily in week 1, 2 daily in week 2, titrated by HAM-A response to up to 5 daily (1100 mg/day) in weeks 5-8
- Population, every finding
- adult outpatients with mild to moderate generalized anxiety disorder (DSM-IV, baseline HAM-A >= 9)
What moved
How to read these marks →“QLS analysis found a significantly greater reduction over time in the mean total HAM-A score for chamomile versus placebo (60 β̂3 = −3.17, 95% CI, −6.29 to −0.45) (p=0.047).”
- Interests
- An author is affiliated with a producer
What did not
“We observed a somewhat greater reduction over time in resting pulse rate during chamomile versus placebo therapy (60 β̂3 = −5.22, 95% CI = −13.64 - 3.20 (p=0.225), but no difference in resting systolic and diastolic blood pressure, or weight.”
- No detected effect on body mass
moderate
- Interests
- An author is affiliated with a producer
- Interests
- An author is affiliated with a producer
- Interests
- An author is affiliated with a producer
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Outpatients with mild to moderate generalized anxiety disorder (DSM IV), minimum baseline HAM-A score ≥ 9
- Participants
- 57
- Comparator
- placebo
- Duration
- 56 days
- Endpoints measured
- 19